Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Craig Jordan

Showing results (21-30 of 218) with videos related to

Pageof 22
Sort By:
Nature Reviews. Clinical Oncology|June 12, 2013
Targeted therapies: Any surprises from selective oestrogen-receptor modulators?V Craig Jordan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Endoxifen: The End, or Are We at the Beginning?V Craig Jordan
Cancer Prevention Research (Philadelphia, Pa.)|March 2, 2017
The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into PracticeV Craig Jordan
Steroids|July 6, 2014
Introduction to a special edition in Steroids of nuclear hormone receptor modulatorsV Craig Jordan
Journal of Medicinal Chemistry|March 7, 2003
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactionsV Craig Jordan
Endocrine-Related Cancer|November 5, 2020
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?V Craig Jordan
F&S Science|May 13, 2022
Serendipity in the search for "morning-after pills" led to clomiphene for the induction of ovulationV Craig Jordan
British Journal of Pharmacology|January 13, 2006
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerV Craig Jordan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2005
Chemoprevention in the 21st century: is a balance best or should women have no estrogen at all?V Craig Jordan
Cancer Cell|March 31, 2004
Selective estrogen receptor modulation: concept and consequences in cancerV Craig Jordan
Pageof 22

Showing results (21-30 of 218) with videos related to

Sort By:
Pageof 22
Nature Reviews. Clinical Oncology|June 12, 2013
Targeted therapies: Any surprises from selective oestrogen-receptor modulators?V Craig Jordan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Endoxifen: The End, or Are We at the Beginning?V Craig Jordan
Cancer Prevention Research (Philadelphia, Pa.)|March 2, 2017
The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into PracticeV Craig Jordan
Steroids|July 6, 2014
Introduction to a special edition in Steroids of nuclear hormone receptor modulatorsV Craig Jordan
Journal of Medicinal Chemistry|March 7, 2003
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactionsV Craig Jordan
Endocrine-Related Cancer|November 5, 2020
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?V Craig Jordan
F&S Science|May 13, 2022
Serendipity in the search for "morning-after pills" led to clomiphene for the induction of ovulationV Craig Jordan
British Journal of Pharmacology|January 13, 2006
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerV Craig Jordan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2005
Chemoprevention in the 21st century: is a balance best or should women have no estrogen at all?V Craig Jordan
Cancer Cell|March 31, 2004
Selective estrogen receptor modulation: concept and consequences in cancerV Craig Jordan
Pageof 22